BRPI0512000A - cápsula estável contra mastigação - Google Patents

cápsula estável contra mastigação

Info

Publication number
BRPI0512000A
BRPI0512000A BRPI0512000-4A BRPI0512000A BRPI0512000A BR PI0512000 A BRPI0512000 A BR PI0512000A BR PI0512000 A BRPI0512000 A BR PI0512000A BR PI0512000 A BRPI0512000 A BR PI0512000A
Authority
BR
Brazil
Prior art keywords
capsule
shell
thickness
respect
stable
Prior art date
Application number
BRPI0512000-4A
Other languages
English (en)
Inventor
Ichiro Okamoto
Yuji Miyamoto
Hidekatsu Nishimura
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of BRPI0512000A publication Critical patent/BRPI0512000A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)

Abstract

CáPSULA ESTáVEL CONTRA MASTIGAçãO. As cápsulas macias sendo facilmente desintegráveis no estómago e evitando qualquer vazamento fácil de teores na mastigação, cujas cápsulas macias encapsulam ácido (2R)-2-propiloctanóico ou seu sal e são caracterizadas pelo fato de que, é realizada pelo menos uma propriedade, preferivelmente todas destas, selecionadas dentre (A) resistência de 150 a 400 N quando medida por um teste de carga de craqueamento; (E) tempo de desintegração de 3 a 10 minutos quando medido por um método de teste de desintegração estipulado na Farmacopéia Japonesa; (C) espessura de 0,05 a 0,50 mm com respeito à parte central da casca da cápsula; (D) espessura de 0,10 a 0,55 mm com respeito à primeira parte de junção da casca da cápsula; (E) espessura de 0,05 a 0,50 mm com respeito à segunda parte de junção da casca da cápsula; e (F) teor de água da casca de cápsula de 5,0 a 9,0%.
BRPI0512000-4A 2004-06-11 2005-06-10 cápsula estável contra mastigação BRPI0512000A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004174576 2004-06-11
JP2005122821 2005-04-20
PCT/JP2005/011092 WO2005120490A1 (ja) 2004-06-11 2005-06-10 咀嚼に対して安定なカプセル

Publications (1)

Publication Number Publication Date
BRPI0512000A true BRPI0512000A (pt) 2008-01-22

Family

ID=35502808

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512000-4A BRPI0512000A (pt) 2004-06-11 2005-06-10 cápsula estável contra mastigação

Country Status (13)

Country Link
US (1) US20080057115A1 (pt)
EP (1) EP1754479A4 (pt)
JP (1) JP5615478B2 (pt)
KR (1) KR20070024722A (pt)
AU (1) AU2005251623A1 (pt)
BR (1) BRPI0512000A (pt)
CA (1) CA2569746A1 (pt)
IL (1) IL179967A0 (pt)
MX (1) MXPA06014396A (pt)
NO (1) NO20065670L (pt)
RU (1) RU2384325C2 (pt)
TW (1) TW200613009A (pt)
WO (1) WO2005120490A1 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08376Y2 (ja) 1990-08-15 1996-01-10 株式会社アルメックス 不溶解性陽極を用いたメッキ装置
WO2007123153A1 (ja) * 2006-04-19 2007-11-01 Ono Pharmaceutical Co., Ltd. 経口投与用カプセル
EP4137128A1 (en) 2008-09-02 2023-02-22 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and a statin, and methods of using same
US9504274B2 (en) 2009-01-27 2016-11-29 Frito-Lay North America, Inc. Methods of flavor encapsulation and matrix-assisted concentration of aqueous foods and products produced therefrom
MX350088B (es) 2009-04-29 2017-08-25 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
NZ720946A (en) 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CN108096209A (zh) 2009-06-15 2018-06-01 阿马里纳制药公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
NZ712068A (en) 2010-11-29 2017-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US8974594B2 (en) * 2011-03-29 2015-03-10 Empire Technology Development Llc Microcapsule corrosion control in reinforced concrete
US20120251484A1 (en) 2011-03-31 2012-10-04 Cp Kelco Aps Cold prepared gel and method for making same
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ITMI20112221A1 (it) * 2011-12-05 2013-06-06 Altergon Sa Formulazioni stabili in capsule di gelatina molle di antiaggreganti piastrinici, acidi grassi omega-3 e amilosio
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
CA3067012C (en) 2012-06-29 2021-10-05 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) * 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US9364441B2 (en) 2013-05-23 2016-06-14 Barlean's Organic Oils, Llc Rotary die system
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
KR101467853B1 (ko) * 2014-04-01 2014-12-03 창성소프트젤 주식회사 탄성 및 접착성이 우수하고 얇은 피막으로 생산성과 붕해도가 향상되는 식물성 연질캡슐 및 그의 조성물과 그 제조방법
US20150335586A1 (en) * 2014-05-20 2015-11-26 R.P. Scherer Technologies, Llc Capsule dispensing container
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
BR112017008715A2 (pt) * 2014-10-31 2018-01-30 Barleans Organic Oils Llc método e aparelho para a fabricação de cápsulas moles
EP4360653A3 (en) * 2015-03-26 2024-07-31 Patheon Softgels Inc. Liquisoft capsules
KR101655407B1 (ko) * 2015-09-02 2016-09-08 주식회사 아미코스메틱 마이크로 캡슐, 및 마이크로 캡슐을 포함하는 화장료 조성물
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
MX2017016719A (es) * 2017-12-19 2020-01-20 Alepharma Soc Anonima Promotora De Inversion De Capital Variable Composición farmacéutica combinada para la prevención de la formación de productos finales de la glicación avanzada.
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA51766A (fr) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
BR112022009189A2 (pt) 2019-11-12 2022-07-26 Amarin Pharmaceuticals Ie Ltd Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
KR102412895B1 (ko) 2020-03-03 2022-07-06 주식회사 휴온스메디컬 시린지의 플런저 고정장치
CN114983962B (zh) * 2021-03-02 2024-03-15 仙乐健康科技股份有限公司 软胶囊囊壳组合物、软胶囊和其制备方法和用途
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3173840A (en) * 1962-04-30 1965-03-16 Lilly Co Eli Separation-resistant capsule
US3927195A (en) * 1974-01-31 1975-12-16 Lilly Industries Ltd Production of capsules
JPH089536B2 (ja) * 1987-10-30 1996-01-31 日清製粉株式会社 腸溶性カプセルの製造方法
US4954346A (en) * 1988-06-08 1990-09-04 Ciba-Geigy Corporation Orally administrable nifedipine solution in a solid light resistant dosage form
JPH04288011A (ja) * 1991-03-14 1992-10-13 Tokai Capsule Kk 軟カプセル剤
JPH0565222A (ja) * 1991-09-09 1993-03-19 Fuji Capsule Kk カプセル剤用プルラン配合皮膜及びカプセル剤
DE69732909T2 (de) * 1996-07-12 2005-08-11 Daiichi Pharmaceutical Co., Ltd. Rasch zerfallende Pressmasse und Verfahren zu ihrer Herstellung
JP3261331B2 (ja) * 1997-03-31 2002-02-25 東海カプセル株式会社 咀嚼用ソフトカプセル剤
JP2000128778A (ja) * 1998-10-20 2000-05-09 Tokai Capsule Kk 捩じり切り開披型ソフトカプセル
KR100759771B1 (ko) * 2000-07-18 2007-10-04 오노 야꾸힝 고교 가부시키가이샤 성상세포 기능 개선제를 유효 성분으로 함유하는 파킨슨병치료제
JP4706950B2 (ja) * 2000-07-18 2011-06-22 小野薬品工業株式会社 アストロサイト機能改善剤を有効成分として含有するパーキンソン病治療剤
CA2453478A1 (en) * 2001-07-18 2003-01-30 Ono Pharmaceutical Co., Ltd. Agent for treatment of cerebral ischemic diseases
US20050058703A1 (en) * 2003-08-01 2005-03-17 Chang Robert C. Gelatin capsules
ES2390055T3 (es) * 2003-10-03 2012-11-06 Ono Pharmaceutical Co., Ltd. Fármaco que contiene ácido(2R)-2-propiloctanoico como principio activo

Also Published As

Publication number Publication date
RU2384325C2 (ru) 2010-03-20
US20080057115A1 (en) 2008-03-06
KR20070024722A (ko) 2007-03-02
EP1754479A4 (en) 2011-03-23
AU2005251623A1 (en) 2005-12-22
RU2006147223A (ru) 2008-07-20
WO2005120490A1 (ja) 2005-12-22
TW200613009A (en) 2006-05-01
NO20065670L (no) 2007-03-12
EP1754479A1 (en) 2007-02-21
JPWO2005120490A1 (ja) 2008-04-03
JP5615478B2 (ja) 2014-10-29
CA2569746A1 (en) 2005-12-22
IL179967A0 (en) 2007-05-15
MXPA06014396A (es) 2007-03-12

Similar Documents

Publication Publication Date Title
Mehler et al. Bulimia Nervosa–medical complications
Utaş et al. Helicobacter pylori eradication treatment reduces the severity of rosacea
Strum et al. Advances in acute and chronic pancreatitis
NO20065670L (no) Kapsel som er stabil mot mastikasjon.
Mansi et al. Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis
Hu et al. Melatonin inhibits endoplasmic reticulum stress-associated TXNIP/NLRP3 inflammasome activation in lipopolysaccharide-induced endometritis in mice
AU2018274937B2 (en) Beta-casein a2 and prevention of inflammation of the bowel
BRPI0618455A2 (pt) composição de geléia
Kivitz et al. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis
BRPI0412489A (pt) composição de confeito mastigável liberando para as superfìcies dentárias uma dose unitária de uma enzima
Singh et al. Pramipexole, ropinirole, and mania in Parkinson’s disease
Guizoni et al. Taurine treatment reverses protein malnutrition-induced endothelial dysfunction of the pancreatic vasculature: The role of hydrogen sulfide
Aabakken et al. Non-steroidal anti-inflammatory drug-induced disease in the distal ileum and large bowel
BRPI0609959A2 (pt) composição anti-inflamatória e/ou analgésica para o intestino compreendendo maltodextrinas ramificadas
BR122021012549B8 (pt) Composição de dissolução oral de melatonina com agente acidificante que torna melatonina solúvel em saliva
Das et al. Lack of vitamin D signalling shifts skeletal muscles towards oxidative metabolism
Smits et al. Digestion and transport across the intestinal epithelium affects the allergenicity of Ara h 1 and 3 but not of Ara h 2 and 6
ES2487634T3 (es) Formulaciones de 4-metilpirazol
Church et al. Prior pregnancy ameliorates the course of intra-abdominal desmoid tumors in patients with familial adenomatous polyposis
Rajaram et al. Serratiopeptidase–A cause for spread of infection
Kroes et al. Ehlers–Danlos syndrome type IV: unusual congenital anomalies in a mother and son with a COL3A1 mutation and a normal collagen III protein profile
Lal et al. Analysis of impact of consumption of proton pump inhibitor on osseo integration of dental implants to the alveolar bone: A systematic critical appraisal.
Jacobson et al. Development of an active site peptide analog of α-fetoprotein that prevents breast cancer
Saban et al. Kinetics of peptide‐induced release of inflammatory mediators by the urinary bladder
Yoon et al. A novel synthetic cathinone, α-pyrrolidinopentiothiophenone (PVT), produces locomotor sensitization in rat: Implications for GSK3β connections in the nucleus accumbens core

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.